Aktuelle Entwicklungen in der Therapie des nicht-kleinzelligen Lungenkarzinoms

Zusammenfassung

Vom 30. 5 bis 3. 6. 2013 fand das Jahrestreffen der American Society of Clinical Oncology (ASCO) statt. Wie immer wurden neue Ideen, Therapieansätze und klinische Studien präsentiert und intensiv diskutiert. Einige neue Entwicklungen bei der Behandlung des fortgeschrittenen nicht-kleinzelligen Lungenkarzinoms (NSCLC) sollen hier kurz vorgestellt werden.

Abstract

In early June the annual meeting of the American Society of Clinical Oncology (ASCO) took place. Several new hypotheses, therapy approaches and clinical studies were presented and intensively discussed. Some new developments in treatment of non-small cell lung cancer will be briefly discussed in this article.

• Literatur

• 1 Mok TSK, Wu YL, Lee JS et al. Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: A randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C). J Clin Oncol 2013; 31: 8021 abstr
• 2 Groschel A, Warth A, Reinmuth N. [Crizotinib – molecular therapy for lung cancer]. Pneumologie 2013; 67: 205-208
• 3 Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175-180
• 4 Shaw AT, Camidge DR, Engelman JA et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 2012; 30: 7508 abstr
• 5 Planchard D, Mazieres J, Riely GJ et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2013; 31: 8009 abstr
• 6 Drilon AE, Wang L, Hasanovic A et al. Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials. J Clin Oncol 2013; 31: 8067 abstr
• 7 Barlesi F, Blons H, Beau-Faller M et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013; 31: 8000 abstr
• 8 Johnson BE, Kris MG, Berry LD et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2013; 31: 8019 abstr
• 9 De Pas T, Giovannini M, Rescigno M et al. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials. Crit Rev Oncol Hematol 2012; 83: 432-443
• 10 Butts C, Murray N, Maksymiuk A et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005; 23: 6674-6681
• 11 Butts CA, Socinski MA, Mitchell P et al. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 2013; 31: 7500 abstr
• 12 Shaw AT, Kim DW, Nakagawa K et al. Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (Profile 1007). Ann Oncol 2012; 23: LBA1_PR
• 13 Shaw AT, Mehra R, Kim D-W et al. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol 2013; 31: 8010 abstr
• 14 Nakagawa K, Kiura K, Nishio M et al. A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP. J Clin Oncol 2013; 31: 8033 abstr
• 15 Besse B, Olaussen KA, Soria JC. ERCC1 and RRM1: ready for prime time?. J Clin Oncol 2013; 31: 1050-1060
• 16 Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991
• 17 Bepler G, Williams CC, Schell MJ et al. Molecular analysis-directed, international, phase III trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013; 31: 8001 abstr
• 18 Friboulet L, Olaussen KA, Pignon JP et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013; 368: 1101-1110
• 19 Liang W, Zhang L. Multitargeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. J Clin Oncol 2013; 31: 8089 abstr
• 20 Hilberg F, Roth GJ, Krssak M et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68: 4774-4782
• 21 Hanna NH, Kaiser R, Sullivan RN et al. Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013; 31: 8034 abstr
• 22 Reck M, Kaiser R, Mellemgaard A et al. Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. J Clin Oncol 2013; 31: LBA8011
• 23 Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132
• 24 Garassino MC, Martelli O, Bettini A et al. TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol 2012; 30: LBA7501
• 25 Okano Y, Ando M, Asami K et al. Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2013; 31: 8006 abstr
• 26 Lazzari C, Novello S, Barni S et al. Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE). J Clin Oncol 2013; 31: LBA8005 abstr
• 27 Schuette W, Nagel S, Schneider C-P et al. 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC). J Clin Oncol 2013; 31: 8013 abstr
• 28 Quoix E, Zalcman G, Oster JP et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011; 378: 1079-1088